Marika A. Rasschaert

AZ Turnhout
Turnhout, VLG, BE 
Clinical Trials:Currently Recruiting for 1 Trial
AZ Turnhout
Turnhout, VLG, BE 

Overview

Marika Rasschaert practices practicing medicine in Turnhout, Belgium.

Her clinical expertise encompasses Lymphofollicular Hyperplasia, Teratoma of the Mediastinum, Severe Acute Respiratory Syndrome (SARS), and Fibrosarcoma.

She is actively involved in clinical research, co-authoring 28 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

AZ Turnhout
Turnhout, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours - BrainStorm Program
A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours - BrainStorm Program
Enrollment Status: Recruiting
Publish Date: January 06, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

28 Total Publications

Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2.
Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2.
Journal: ESMO open
Published: October 23, 2025

Frequently Asked Questions about Marika A. Rasschaert

Is Marika A. Rasschaert a top-rated expert for Lymphofollicular Hyperplasia?

MediFind is an objective health platform that identifies experts based on real-world data. Marika A. Rasschaert is classified as an Experienced expert for Lymphofollicular Hyperplasia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marika A. Rasschaert participate in research or clinical trials?

Yes. Marika A. Rasschaert has published 28 articles and abstracts on conditions like Lymphofollicular Hyperplasia. You can view a list of Marika A. Rasschaert's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Rasschaert's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile